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Glossary 
DM    Diabetes mellitus 
FBS     Fasting blood sugar 
HbA(1c)    Haemoglobin (A1c) 
LDL    Low density lipoprotein 
HDL    High density lipoprotein 
DCCT   Diabetes Control and Complication Trial  
US    United States 
DKA                               Diabetic ketoacidosis 
MODY                            Maturity-onset diabetes of the young  
GDM                              Gestational diabetes mellitus  
ESRD                             End-stage renal disease  
LADA                             latent autoimmune diabetes of the adult  
UKPDS                          United Kingdom Prospective Diabetes Study 
CAD                               Coronary artery disease 
ADA                               American Diabetes Association 
GHb                               Glycated hemoglobin 
AACC                             American Association for Clinical Chemistry  
DSMEs                      Diabetes Self-Management Education Programs  
AADE                         American Association of Diabetes Educators  
SMBG                         Self-monitoring of blood glucose 
MIEP                          Multidisciplinary Intensive Education Program 
PWH                           Prince of Wales Hospital  
SPSS                           Statistical Package for Social Sciences 
BMI                            Body mass index 
PG                              Plasma Glucose 
  
ABSTRACT 
 
Diabetes mellitus is a chronic disease that requires long-term medical 
attention both to limit the development of its devastating complications and 
to manage them when they do occur. It is an expensive disease. It is a 
common disease in Sudan. It is a cause of major morbidity and mortality. 
The objectives of this study were to assess patient’s glycaemic control and to 
assess the impact of patient’s therapeutic education on the control of the 
diease, also to assess effect of body weight on the control. The study was 
conducted at one of the best well formed diabetic center in Sudan (Gabber 
Abu Elaaz) where all facilities for patient’s therapeutic education, 
diabetologist, diabetic nurse, dietician, dermatologist, ophthalmologist, 
surgical care, investigations, were available for follow-up. Hundred adult 
diabetics, fifty were males, fifty were females were selected randomly and 
were assessed clinically and biochemically, their level of knowledge 
regarding diabetes, its management and complications, and their body mass 
index were assessed. The mean age was (57.9) years, (range 35–85 years), 
mean duration of diabetes, was (8.7) years.  Most of these patients were 
either illiterate or just received primary education (77%).The 
symptomatology of these patients gives clear indication to their uncontrolled 
blood sugar levels, and complications. Polyuria, polydipsia, fatigue, 
numbness, impairment of vision, were the most prevalent symptoms. 
Presence of retinopathy & peripheral neuropathy have significant correlation 
to duration of DM. 
Fasting blood glucose & HBA1c for these patients showed that, 76% of 
these patients had FBS levels above the normal range, and only 14% had 
HBA1c less 6.5%.  
  
Level of knowledge was adequate, 81% were between good level and 
moderate level of knowledge regarding awareness about diabetes 
complications & diet, but the weakness appeared in the aspect of diabetes 
management and its complications.  
No correlation between level of knowledge and the glycemic control was 
found.  
60% of the patients were overweight or obese. No significant correlation 
between BMI and glycemic control. 
Self-monitoring of blood glucose using glucometers was practiced by  
(11%).  
Few had regular exercise practice. Females were less active than males (22%). 
Although the degree of knowledge is acceptable, most patients were not 
well controlled. 
Specialized programs of diabetes education, simple educational tools and well trained 
educators were recommended to address older patients, illiterate groups and those with 
language difficulties to improve the glycaemic control.  
 
 
 
 
 
 
 
 
 
 
 
  
  ﺺ اﻷﻃﺮوﺣﺔﻣﻠﺨ
 
و هﻮ . داء اﻟﺴﻜﺮ ﻣﺮض ﻣﺰﻣﻦ ﻳﺘﻄﻠﺐ رﻋﺎﻳﺔ ﻃﺒﻴﺔ ﻃﻮﻳﻠﺔ اﻟﻤﺪى ﺗﺸﻤﻞ ﺗﻌﻘﻴﺪاﺗﻪ اﻟﻤﺪﻣﺮة و ﻋﻼﺟﻬﺎ ﻋﻨﺪ اﻟﻈﻬﻮر
  .ﻣﺮض ﻋﺎﻟﻲ اﻟﺘﻜﻠﻔﺔ اﻟﻌﻼﺟﻴﺔ و هﻮ ﻣﻦ اﻷﻣﺮاض اﻟﺸﺎﺋﻌﺔ ﻓﻲ اﻟﺴﻮدان و ﺳﺒﺐ ﻓﻲ اﻟﺘﻌﻘﻴﺪات اﻟﻤﺮﺿﻴﺔ و اﻟﻮﻓﻴﺎت
ﺪى ﻣﺮﺿѧﻰ اﻟѧﺴﻜﺮ و ﺗﺤﺪﻳѧﺪ اﺛѧﺮ أهѧﺪاف هѧﺬﻩ اﻟﺪراﺳѧﺔ ﺗﻘﻴѧﻴﻢ ﺿѧﺒﻂ ﻣѧﺴﺘﻮى اﻟѧﺴﻜﺮ ﻓѧﻲ اﻟѧﺪم ﻟѧ 
  .آﺬﻟﻚ ﻟﺘﺤﺪﻳﺪ اﺛﺮ وزن اﻟﺠﺴﻢ ﻓﻲ ﺗﻨﻈﻴﻢ اﻟﺴﻜﺮ. اﻹرﺷﺎد اﻟﻌﻼﺟﻲ ﻟﻠﻤﺮﻳﺾ ﻓﻲ ﺗﻨﻈﻴﻢ اﻟﺴﻜﺮ
أﺟﺮﻳﺖ اﻟﺪراﺳﺔ ﻓﻲ اﺣﺪ ﻣﺮاآﺰ اﻟﺴﻜﺮ اﻟﻤﺘﻤﻴﺰة ﻓﻲ اﻟﺴﻮدان و هﻮ ﻣﺮآﺰ ﺟﺎﺑﺮ أﺑﻮ اﻟﻌﺰ، اﻟﺬي 
ﺮوع ﻟﻄѧﺐ اﻟﺒﺎﻃﻨﻴѧﺔ، ﻳﻀﻢ آﻞ وﺳﺎﺋﻞ اﻟﺘﻌﻠﻴﻢ اﻟﻌﻼﺟﻲ ﻟﻠﻤﺮﺿﻰ، و آﻮادر ﻃﺒﻴﺔ ﻣﺘﺨﺼﺼﺔ ﻓﻲ أﻏﻠﺐ ﻓѧ 
  .اﻟﺦ.... اﻟﻌﻴﻮن، اﻟﺠﺮاﺣﺔ 
ﺗﻢ ﻋﺸﻮاﺋﻴًﺎ اﺧﺘﻴﺎر ﻣﺎﺋﺔ ﻣﺮﻳﺾ ﻣﻦ اﻟﺒﺎﻟﻐﻴﻦ ﺧﻤﺴﻴﻦ ﻣﻦ اﻟﺬآﻮر و ﺧﻤﺴﻴﻦ ﻣﻦ اﻹﻧѧﺎث ﻹﺟѧﺮاء 
ﺗѧﻢ ﺗﺤﺪﻳѧﺪ ﻣѧﺴﺘﻮى اﻟﻤﻌﺮﻓѧﺔ ﺑѧﺎﻟﻤﺮض، . اﻟﺪراﺳﺔ ﺣﻴﺚ ﺗﻢ ﺗﻘﻴѧﻴﻢ اﻟﺤѧﺎﻻت ﺳѧﺮﻳﺮﻳًﺎ و ﻣﻌﻤﻠﻴѧًﺎ و ﺗﺸﺨﻴѧﺼﻴﺎ ً
  .ﻋﻼﺟﻪ و ﻣﻀﺎﻋﻔﺎﺗﻪ و دﻟﻴﻞ آﺘﻠﺔ اﻟﺠﺴﻢ
و ﻣﺘﻮﺳѧѧﻂ ﻓﺘѧѧﺮة "  ﺳѧѧﻨﺔ،58 – 53اﻷﻋﻤѧѧﺎر ﻣѧѧﻦ " ﺳѧѧﻨﺔ 9.75ﻂ ﻋﻤѧѧﺮ اﻟﻤﺮﺿѧѧﻰ آѧѧﺎن ﻣﺘﻮﺳѧѧ
%. 77ﻣﻌﻈѧﻢ اﻟﻤﺮﺿѧﻰ ﻣѧﻦ اﻷﻣﻴѧﻴﻦ أو ﻣﻤѧﻦ ﺗﻠﻘѧﻮا اﻟﺘﻌﻠѧﻴﻢ اﻷوﻟѧﻲ .  ﺳѧﻨﺔ 7.8اﻹﺻﺎﺑﺔ ﺑﺎﻟﻤﺮض آﺎﻧѧﺖ 
أﻋѧѧﺮاض اﻟﻤѧѧﺮض ﻋﻨѧѧﺪ هѧѧﺆﻻء دﻟﻴѧѧﻞ واﺿѧѧﺢ ﻋﻠѧѧﻰ ﻋѧѧﺪم اﻟѧѧﺴﻴﻄﺮة ﻋﻠѧѧﻰ ﻣѧѧﺴﺘﻮى اﻟѧѧﺴﻜﺮ ﻓѧѧﻲ اﻟѧѧﺪم و 
  .آﺜﺮة اﻟﺸﺮب ، اﻹﻋﻴﺎء، ﺿﻌﻒ ﺣﺪة اﻟﻨﻈﺮ، ﺗﻨﻤﻴﻞ اﻷﻃﺮافﻣﻀﺎﻋﻔﺎﺗﻪ و هﻲ ﺗﺸﻤﻞ آﺜﺮة اﻟﺘﺒﻮل، 
  .ﻇﻬﻮر اﻋﺘﻼل ﺷﺒﻜﻴﺔ اﻟﻌﻴﻦ و اﻷﻋﺼﺎب اﻟﻄﺮﻓﻴﺔ ﻟﻪ ﻋﻼﻗﺔ واﺿﺤﺔ ﺑﻔﺘﺮة ﻣﺮض اﻟﺴﻜﺮ
% 67 س ﻟﻠﻤﺮﺿѧﻰ ﻳﻮﺿѧﺢ أن 1ﻣѧﺴﺘﻮى اﻟѧﺴﻜﺮ ﻓѧﻲ اﻟѧﺪم ﻓѧﻲ ﺣﺎﻟѧﺔ اﻟѧﺼﻴﺎم و هﻴﻤﻮﻏﻠѧﻮﺑﻴﻦ أ 
 1ﻣѧﻨﻬﻢ ﻓﻘѧﻂ ﻳﺤﻤѧﻞ هﻴﻤﻮﻏﻠѧﻮﺑﻴﻦ أ % 41ﻣﻨﻬﻢ ذو ﻣﺴﺘﻮى ﻟﻠﺴﻜﺮ ﻓﻲ اﻟﺪم أﻋﻠﻰ ﻣﻦ اﻟﻤﻌﺪل اﻟﻄﺒﻴﻌѧﻲ و 
   % .5.6س أﻗﻞ ﻣﻦ 
ﺑѧﻴﻦ ﺟﻴѧﺪ و وﺳѧﻂ ﻣѧﻦ ﺣﻴѧﺚ اﻟѧﻮﻋﻲ % 18وُﺟѧﺪ ﻓѧﻲ اﻟﺪراﺳѧﺔ أن ﻣѧﺴﺘﻮى اﻟﻤﻌﺮﻓѧﺔ ﺟﻴѧﺪ ﺣﻴѧﺚ 
ﻇﻬѧﺮت ﻧﻘﻄѧﺔ اﻟѧﻀﻌﻒ ﻓѧﻲ اﻟﻤﻌﺮﻓѧﺔ ﺑﻌѧﻼج اﻟﻤѧﺮض و . ﺑﻤѧﻀﺎﻋﻔﺎت ﻣѧﺮض اﻟѧﺴﻜﺮ و اﻟﻨﻈѧﺎم اﻟﻐѧﺬاﺋﻲ 
  .ﻣﻀﺎﻋﻔﺎت اﻟﻌﻼج
ﺎﻟﻤﺮض و اﻟﺴﻴﻄﺮة ﻋﻠﻰ ﻣﺴﺘﻮى اﻟﺴﻜﺮ ﻓѧﻲ ﻟﻢ ﺗﻈﻬﺮ ﻓﻲ اﻟﺪراﺳﺔ ﻋﻼﻗﺔ ﺑﻴﻦ ﻣﺴﺘﻮى اﻟﻤﻌﺮﻓﺔ ﺑ 
  .اﻟﺪم
  
ﻟѧﻢ ﺗﻈﻬѧﺮ أﻳѧﻀًﺎ ﻋﻼﻗѧﺔ ﺑѧﻴﻦ دﻟﻴѧﻞ آﺘﻠѧﺔ . ﻣѧﻦ اﻟﻤﺮﺿѧﻰ آѧﺎﻧﻮا ﻳﺘѧﺼﻔﻮن ﺑﺎﻟﺒﺪاﻧѧﺔ واﻟѧﺴﻤﻨﺔ% 06
  .اﻟﺠﺴﻢ و اﻟﺴﻴﻄﺮة ﻋﻠﻰ اﻟﻤﺮض
  .ﻣﻦ اﻟﻤﺮﺿﻰ ﻳﻤﺎرﺳﻮن اﻟﻔﺤﺺ اﻟﺸﺨﺼﻲ ﻟﻠﺴﻜﺮ ﺑﻮاﺳﻄﺔ أﺟﻬﺰة ﻗﻴﺎس اﻟﺴﻜﺮ ﻓﻲ اﻟﺪم% 11
  %(.22)اﻹﻧﺎث أﻗﻞ ﻧﺸﺎﻃًﺎ ﻣﻦ اﻟﺬآﻮر . ﺔﻗﻠﻴﻞ ﻣﻦ اﻟﻤﺮﺿﻰ ﻳﻤﺎرﺳﻮن ﺗﻤﺎرﻳﻦ رﻳﺎﺿﻴ
رﻏﻢ أن درﺟﺔ اﻟﻤﻌﺮﻓﺔ أو اﻟﻮﻋﻲ ﺑﺎﻟﻤﺮض ﻣﻘﺒﻮﻟﺔ أﻻ أن آﺒﺢ ﺟﻤﺎح اﻟﻤﺮض ﻻ ﻳﺘﺄﺗﻰ ﻣﻊ هѧﺬﻩ 
  .اﻟﺤﻘﻴﻘﺔ ﺣﻴﺚ أن ﻣﻌﻈﻢ اﻟﻤﺮﺿﻰ ﻻ ﻳﺴﻴﻄﺮون ﻋﻠﻰ اﻟﺴﻜﺮ ﻓﻲ اﻟﺪم ﺑﺎﻟﻄﺮﻳﻘﺔ اﻟﻤﺜﻠﻲ
ﻞ ﻣﺒѧﺴﻄﺔ و اﻟﺘﻮﺻﻴﺎت ﻓѧﻲ اﻟﺪراﺳѧﺔ ﺗѧﺸﻤﻞ إﻗﺎﻣѧﺔ ﺑѧﺮاﻣﺞ ﺗﻮﻋﻴѧﺔ ﺧﺎﺻѧﺔ ﺑﻤѧﺮض اﻟѧﺴﻜﺮ ﺑﻮﺳѧﺎﺋ 
ﻣﺸﺮﻓﻴﻦ ﻣﺆهﻠﻴﻦ ﻟﻤﺠﺎﺑﻬﺔ اﻟﻤﺮﺿﻰ اﻟﻤﺴﻨﻴﻦ، اﻷﻣﻴﻴﻦ و اﻟﺬﻳﻦ ﻳﻌﺎﻧﻮن ﻣﻦ ﻋﻘﺒﺎت ﻓѧﻲ اﻟﻠﻐѧﺔ و اﻟﻤﺨﺎﻃﺒѧﺔ 
 .آﻞ ذﻟﻚ ﻟﻴﺘﺴﻨﻰ ﻟﻠﻤﺮﺿﻰ اﻟﺴﻴﻄﺮة ﻋﻠﻰ اﻟﻤﺮض
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INTRODUCTION 
 
Type 2 diabetes mellitus is a group of disorders characterized by 
hyperglycemia and associated with microvascular (optic, renal, and possibly 
neuropathic) and macrovascular (coronary and peripheral vascular) 
complications. Unlike type 1 diabetes mellitus, the patients are not 
absolutely dependent upon insulin for life, even though many of these 
patients ultimately are treated with insulin.  
 Hyperglycemia is produced by lack of endogenous insulin, which is either 
absolute, as in type 1 diabetes mellitus, or relative, as in type 2 diabetes 
mellitus. Relative insulin deficiency usually occurs because of resistance to 
the action of insulin in muscle, fat, and the liver. This pathophysiologic 
abnormality results in decreased glucose transport in muscle, elevated 
hepatic glucose production, and increased breakdown of fat. (1) 
Diabetes mellitus is a chronic disease that requires long-term medical 
attention both to limit the development of its devastating complications and 
to manage them when they do occur.  
 Diabetes mellitus, a leading cause of death in the United States, remains 
undiagnosed in more than 5 million people. While screening for this disease 
is a key to reduce its complications, morbidity and mortality, the 
recommendations for identifying and testing at-risk populations are 
debatable. (2) 
The prevalence of diabetes mellitus in Sudan is not yet determined, but the 
prevalence of diabetes mellitus in countries like US in adults aged 20 and 
older is estimated to be 7.8%, according to the Third National Health and 
  
Nutrition Examination Survey. Of the estimated 15.6 million Americans 
with diabetes, 5.4 million (35%) are unaware that they have the disease. (3)  
Undiagnosed diabetes is not a benign condition, and many patients have 
serious complications by the time the disease is diagnosed. (4)  
Generally, screening for a particular disease is likely to be beneficial if the 
disease is serious enough to warrant medical attention; effective treatment is 
available; and the prognosis for the disease is better if it is diagnosed and 
treated early. Further, the screening and diagnostic methods should have 
high accuracy and be available at low cost and with little inconvenience and 
minimal discomfort relative to the benefits of diagnosis. (5)  
The American College of Physicians recommends screening in patients who 
are 18 years of age or older and have one or more of the following 
characteristics: family history of type 2 diabetes, age over 50, weight 25% 
over ideal body weight, gestational diabetes, and ethnicity known to be at 
high risk of diabetes.  
The Canadian Task Force agrees with screening in patients who are 18 years 
of age or older and have gestational diabetes or a family history of type 2 
diabetes, and it presents peripheral vascular disease as an additional risk 
factor. The task force does not mention as risk factors obesity, greater age, 
and ethnicity at high risk of diabetes.  
The US Preventive Services Task Force concurs with initiating screening at 
age of eighteen years in the presence of risk factors that include family 
history, gestational diabetes, and high-risk ethnicity. They also agree with 
screening when obesity is present in patients over 40 years of age. (5)  
 The importance of glycaemic control in the prevention of micro vascular 
complications has been confirmed in both type 1 and type 2 diabetic patients. 
However, achievement of optimal glycaemic control remains a major 
  
challenge to health-care providers. In the Diabetes Control and Complication 
Trial (DCCT) where patients were closely monitored, only 44% of patients 
in the intensively-treated group achieved the goal of glycosylated 
haemoglobin 6.05% at least once. Identification of factors that determine 
glycaemic control may help health-care providers to manage these high-risk 
patients more effectively. (6)   
The relationships between glycaemic control and some potential determining 
factors, with particular emphasis on therapeutic patient education, self-
monitoring, treatment regimen, insulin resistance and pancreatic ß-cell 
function. 
In this study I’m going to assess the impact of body weight and patient 
education on the glycaemic control of type 2 diabetic patients.   
  
 
LITERATURE REVIEW 
 
Type 2 diabetes typically occurs in individuals older than 40 years who have a 
family history of diabetes. Type 2 diabetes is characterized by peripheral insulin 
resistance with an insulin-secretory defect that varies in severity. These defects lead to 
increased hepatic gluconeogenesis, which produces fasting hyperglycemia. Most patients 
(90%) who develop type 2 diabetes are obese, and obesity itself is associated with insulin 
resistance, which worsens the diabetic state.  
Since patients with type 2 diabetes retain the ability to secrete some 
endogenous insulin, those who are taking insulin do not develop DKA if for 
some reason they stop taking it. Therefore, they are considered to require 
insulin but not to depend on insulin. Moreover, patients with type 2 diabetes 
often do not need treatment with oral antidiabetic medication or insulin if 
they lose weight by successfully adhering to a physician-directed weight loss 
program including strict diet control and exercise.(7)  
A variety of other types of diabetes, previously called "secondary diabetes," 
are caused by other illnesses or medications. Depending on the primary 
process involved (i.e., destruction of pancreatic beta cells or development of 
peripheral insulin resistance), these types of diabetes behave similarly to 
type 1 or type 2 diabetes. The most common are diseases of the pancreas that 
destroy the pancreatic beta cells (e.g., hemochromatosis, pancreatitis, cystic 
fibrosis, pancreatic cancer); hormonal syndromes that interfere with insulin 
secretion (e.g., pheochromocytoma) or cause peripheral insulin resistance 
  
(e.g., acromegaly, Cushing syndrome, pheochromocytoma); and drug-
induced diabetes (e.g., phenytoin, glucocorticoids, estrogens). (7)  
  
Maturity-onset diabetes of the young (MODY) is a form of type 2 diabetes 
that affects many generations in the same family with onset in individuals 
younger than 25 years. Several types exist.  
Gestational diabetes mellitus (GDM) is defined as any degree of glucose 
intolerance with onset or first recognition during pregnancy.  Untreated 
GDM can lead to fetal macrosomia, hypoglycemia, hypocalcemia, and 
hyperbilirubinemia. In addition, mothers with GDM have higher rates of 
cesarean delivery and chronic hypertension. To diagnose GDM, a 50-gram 
glucose screening test should be done at 24-28 weeks of gestation. This is 
followed by a 100-gram, 3-hour oral glucose tolerance test if the 1-hour post 
screen plasma glucose concentration is greater than 140 mg/dL. (7) 
The morbidity and mortality associated with diabetes are related to the short- 
and long-term complications. These complications include hypoglycemia 
and hyperglycemia, increased risk of infections, microvascular 
complications (i.e., retinopathy, nephropathy), neuropathic complications, 
and macrovascular disease. Diabetes is the major cause of blindness in 
adults aged 20-74 years, as well as the leading cause of nontraumatic lower-
extremity amputation and end-stage renal disease (ESRD). (9) 
 Incidence is essentially equal in females and males in all populations.  Type 
2 diabetes is becoming increasingly common because more people are living 
longer (diabetes prevalence increases with age). It is also being seen more 
frequently in younger people in association with the rising prevalence of 
childhood obesity. Although type 2 diabetes still occurs most commonly in 
  
adults aged 40 years and older, the incidence of disease is increasing more 
rapidly in adolescents and young adults than in other age groups. (10) 
Correctly determining whether a patient has type 1 or type 2 diabetes is 
extremely important, since patients with type 1 diabetes are dependent on a 
continuous source of exogenous insulin and carbohydrates for survival. 
Patients with type 2 diabetes, on the other hand, may not need treatment for 
hyperglycemia during periods of fasting or decreased oral intake. (8) 
A patient whose diabetes is controlled with diet or an oral antidiabetic agent 
clearly has type 2 diabetes. A lean patient who has had diabetes since 
childhood, has always been dependent on insulin, or has a history of DKA 
almost certainly has type 1 diabetes.  
Distinguishing the type of diabetes becomes more difficult in patients who 
are treated with insulin and are younger but clinically appear to have type 2 
diabetes and in older patients with late onset of diabetes who, nonetheless, 
take insulin and seem to share characteristics of patients with type 1 
diabetes. (This latter group now is said to have latent autoimmune diabetes 
of the adult [LADA]). When in doubt, treat with insulin and monitor glucose 
levels closely. Recently, reports have surfaced of many patients, who 
presented as adolescents or young adults with classic DKA but subsequently 
were found to have type 2 diabetes.  
Many patients with type 2 diabetes are asymptomatic and go undiagnosed 
for many years. Studies suggest that the average patient with new-onset type 
2 diabetes actually has had diabetes for at least 4-7 years before the 
diagnosis. Of patients with type 2 diabetes, 25% are believed to have 
retinopathy, 9% neuropathy, and 8% nephropathy at the time the diagnosis is 
made.  
  
Chronic hyperglycemia is associated with an increased risk of developing 
the microvascular complications of diabetes, as elegantly demonstrated in 
the Diabetes Control and Complications Trial (DCCT) for type 1 diabetes 
and the United Kingdom Prospective Diabetes Study (UKPDS) for type 2 
diabetes. In the DCCT, intensive therapy designed to maintain normal blood 
glucose levels greatly reduced the development and progression of 
retinopathy, microalbuminuria, proteinuria, and neuropathy as assessed over 
a 7-year period. Intensive therapy was not associated with increased 
mortality or incidence of major macrovascular events and did not decrease 
the quality of life, although it did increase the likelihood of severe 
hypoglycemic episodes. (9) 
In the UKPDS trial, more than 5000 patients with type 2 diabetes were 
studied for up to 15 years. Those in the intensively treated group had a 
significantly lower rate of progression of microvascular complications than 
those receiving standard care. Rates of macrovascular disease were not 
altered except in the metformin monotherapy arm, in which risk of 
myocardial infarction was significantly decreased. Moreover, severe 
hypoglycemia occurred much less often than in patients with type 1 diabetes 
in the DCCT. (9)  
The goal of treatment with oral ant-diabetic agents is to lower blood glucose 
levels into the near-normal range (i.e., pre-prandial blood glucose levels of 
80-140 mg/dL; HbA1c levels <8%) and maintain them in this range 
throughout the rest of the patient's life. Patients with no or mild symptoms 
should be treated initially with MNT (previously known as diet therapy), and 
MNT should be encouraged throughout the course of a patient's treatment. In 
the ED, drugs are started when a patient presents with moderate-to-marked 
symptoms of diabetes.  
  
Some patients should not aim for near-normal blood glucose levels. In 
elderly patients who have a life expectancy of <5 years or any patient with a 
terminal disease, tight control is unnecessary. Patients with known CAD or 
cerebrovascular disease should have higher pre-prandial blood glucose 
targets (e.g., 100-160 mg/dL) to prevent extreme hypoglycemia.  
Some patients have advanced microvascular, and neuropathic diabetic 
complications and may not benefit particularly from maintenance of near 
euglycemia. Finally, patients with hypoglycemia unawareness (i.e., the lack 
of adrenergic warning signs of hypoglycemia) or those with recurrent 
episodes of severe hypoglycemia (i.e., hypoglycemia requiring treatment by 
another) also should have higher target levels.  
Throughout the treatment of a patient with type 2 diabetes, adherence to 
MNT and exercise should be stressed because behavior modification can 
have a large impact on the degree of diabetic control achieved.  
Although most emergency physicians rarely start diabetics on new therapy, 
being acquainted with the medications used and their adverse effects and 
contraindications is useful.  
 
Glycaemic control 
The importance of glycaemic control in the prevention of microvascular 
complications has been confirmed in both type 1 and type 2 diabetic patients. 
However, achievement of optimal glycaemic control remains a major 
challenge to health-care providers. Identification of factors that determine 
glycaemic control may help health-care providers to manage these high-risk 
patients more effectively. 
Two large, well publicised trials have shown that fewer microvascular 
complications occur with better metabolic control in people with insulin 
  
dependent diabetes. (11)  While poor metabolic control remains one of 
several important risk factors for the complications of diabetes. (12)  
These trials have strengthened the conviction that the burden of morbidity 
and mortality can be lightened by improved care. The outcome of a large 
trial assessing the relative contribution of metabolic control to complications 
in people with noninsulin dependent diabetes is awaited. (13)  
It seems reasonable, however, to assume that achieving better glycaemic 
control is also worth while in this group as the mechanism of microvascular 
damage is thought to be the same as in people with insulin dependent 
diabetes. The question of optimal metabolic control is therefore now in sharp 
focus. (14)  
Measurement of glycated haemoglobin is the most widely used method of 
evaluating long term glycaemic control.17 Doctors' awareness of this measure 
has been shown to be associated with better glycaemic control for their 
patients, and patients are invited to evaluate their own achievements in 
controlling their diabetes in terms of this measure. (15)  
The DCCT, which was completed in1993, showed that the risks for 
development and progression of the chronic complications of diabetes are 
closely related to the degree of glycemic control, as measured by serial GHb 
determinations. The U.K. prospective Diabetes Study (UKPDS), which was 
completed in 1998, showed results similar to those of the DCCT in patients 
with type 2 diabetes . Based on the DCCT results, the American Diabetes 
Association 
(ADA) now recommends that a primary treatment goal in diabetes should be 
blood Glucose control at least equal to that achieved in the intensively 
treated cohort in the DCCT. They further recommend a specific GHb target 
(7.0%) and action limit (8%) based on the DCCT results .Thus, the DCCT 
  
results set the stage for establishing specific diabetes treatment goals that 
used GHb as an index of mean blood glucose values. However, when the 
DCCT ended in 1993, GHb test results were not standardized among 
laboratories, which pre-vented optimal clinical use of the test with respect to 
the new ADA recommendation s .Because of the positive impact 
standardization 
of GHb determinations would have on the care of diabetic patients, and in 
anticipation of the re p o rt of the DCCT results, the American Association 
for Clinical Chemistry (AACC) Standards Committee 
established a GHb standardization subcommittee in April 1993. The goal of 
the subcommittee was to develop a plan for GHb standardization that would 
ultimately allow individual clinical laboratories to relate their GHb assay 
results to those obtained in the DCCT. (16) 
 
Measuring glycated haemoglobin, the "gold standard" method for assessing 
glycaemic control, is therefore fixed firmly in the sights of the clinical target 
setters. In its advice to general practitioners, the British Diabetic Association 
offers targets for haemoglobin A1 and A1c with the proviso that they may 
have to be adjusted according to the variation in reference ranges of different 
assays. (17)  
The Royal College of General Practitioners states that a level of 
haemoglobin A1 of less than 9% should be the goal for those with insulin 
dependent diabetes and those with non-insulin dependent diabetes who are 
aged under 65. (18)   
The St Vincent Declaration's guidelines for children and adolescents with 
diabetes state that glycated haemoglobin should be "around the upper normal 
  
range, not lower than the mean of normal range (indicating hypoglycaemia) 
and not more than 1-2% above normal range.(19)  
The American Diabetic Association has recently abandoned its precise 
categories of control ("good," "acceptable," and "poor") in favour of this 
more general approach 
                         Good  Acceptable  Poor  Very poor 
Haemoglobin A1 
 (Normal 5.0-7.5)        <7.5   7.5-8.7   8.8-10   >10 
Haemoglobin A1c 
 (normal 4.0-6.0)        <6.0   6.0-7.0   7.1-8.1  >8.0 
 
Glycaemic control has many potential determining factors, particular 
emphasis on therapeutic patient education, self-monitoring, body weight will 
be discussed. (20) 
Therapeutic patient education 
One of the critical components of initial diabetes care is patient education. 
The effectiveness of diabetes education on patient outcomes has been 
documented. Current evidence suggests that diabetes education has an 
overall beneficial impact on health and psychosocial outcomes. Specifically, 
improved patient knowledge and behavior has been shown to improve 
glycemic control.To limit variation in educational interventions and provide 
a consistent format, the National Standards for Diabetes Self-Management 
Education Programs (DSMEs) were developed and recently revised. These 
standards state that patients with diabetes require both knowledge and skills 
to manage their disease, which result in more informed choices and 
beneficial changes in behavior. 
  
 Low literacy is an important barrier for patients with diabetes, but 
interventions to address low literacy have not been well examined.  To 
examine the role of literacy on the effectiveness of a comprehensive disease 
management program for patients with diabetes. Analysis of the influence of 
literacy on glycemic control and systolic blood pressure using data from a 
randomized controlled trial (conducted from February 2001 through April 
2003) of a comprehensive diabetes management program. Participants were 
217 patients aged 18 years or older with type 2 diabetes and poor glycemic 
control (glycosylated hemoglobin [HbA1c] levels > or =8.0%) and 
presenting to a US academic general internal medicine practice.  All 
communication to patients was individualized and delivered to enhance 
comprehension among patients with low literacy. Intervention patients 
received intensive disease management from a multidisciplinary team. 
Control patients received an initial management session and continued with 
usual care. Achievement of goal HbA1c levels and systolic blood pressure at 
12-month follow-up for control and intervention patients stratified by 
literacy status.  Complete 12-month data were available for 193 patients 
(89%). Among patients with low literacy, intervention patients were more 
likely than control patients to achieve goal HbA1c levels (< or =7.0%) (42% 
vs 15%, respectively; adjusted odds ratio [OR], 4.6; 95% confidence interval 
[CI], 1.3 to 17.2; P = .02). Patients with higher literacy had similar odds of 
achieving goal HbA1c levels regardless of intervention status (24% vs 23%; 
adjusted OR, 1.0; 95% CI, 0.4 to 2.5; P = .98). Improvements in systolic 
blood pressure were similar by literacy status. The study concluded that 
Literacy may be an important factor for predicting who will benefit from an 
intervention for diabetes management. A diabetes disease management 
program that addresses literacy may be particularly beneficial for patients 
  
with low literacy, and increasing access to such a program could help reduce 
health disparities. (21) 
 
 In study to assess the secondary Effect of culturally appropriate health 
education on glycaemic control and knowledge of diabetes in British 
Pakistani women with type 2 diabetes mellitus assessment of 105 British 
Pakistani women within a larger randomized controlled trial of 200 Pakistani 
patients with diabetes. The trial used one-to-one structured diabetes health 
education, delivered by a linkworker with pictorial flashcards as a visual aid. 
Earlier published results from this study have shown that the women in the 
study knew less about diabetes and had poorer glycaemic control than men, 
which is why this assessment was performed to see what happened to them 
when they received appropriate health education. All patients were assessed 
before and 6 months after intervention by questionnaire and haemoglobin 
A1c blood tests to measure their overall blood sugar control. Nearly 
everyone improved their knowledge scores after 6 months in the intervention 
group, with women showing a catch-up improvement such that they equalled 
men. Multiple regression analysis found that glycaemic control improved in 
women receiving health education. Although this method of health 
education improved knowledge and glycaemic control in women in this 
sample, illiterate women did not do as well as their literate peers, continuing 
to score less on knowledge parameters. They also did not show an 
improvement in glycaemic control. (22) 
Appropriate self-management behavior, in turn, improves clinical indicators 
and reduces the risk of secondary complications. Based on this evidence-
based supposition, the seven outcome areas of diabetes education recently 
defined by the American Association of Diabetes Educators (AADE) and the 
  
10 content areas identified in the National Standards for DSMEs are stated in 
behavioral terms—with expectations to guide the educators in their method 
of delivery of promoting behavior change, rather than the traditional 
approach of focusing on knowledge.  
A diabetes educator aims to modify patients’ behavior by providing 
knowledge, changing attitude and teaching skills with particular emphasis on 
self care. It can be a slow and painstaking process. 
Patient education programme, and outpatient counselling improve glycaemic 
control, regarding smoking habit, Non-smokers found to have a lower HbAlc 
than smokers. Tobacco has been shown to be a predictor for subsequent 
development of diabetes in middle-aged men. In both type 1 and type 2 
patients. 
The most impressive study in those who received intensive education 
programs, was the dramatic reduction in leg amputation after education by a 
diabetes educator.  
Meal planning and dietary modifications are important aspects of diabetes 
education. In type 1 diabetes, there were close associations between careful 
meal planning and HbAlc. Type 2 diabetic patients who had received dietary 
instructions also showed an improvement in glycaemic control, irrespective 
of the methods of instruction. On the other hand, type 2 diabetic patients who 
perceived absence of dietary recommendation had poor glycaemic control. 
Diabetes self-management training  
Self-monitoring of blood glucose (SMBG) is an important component of 
modern therapy for diabetes mellitus. SMBG has been recommended for 
people with diabetes and their health care professionals in order to achieve a 
specific level of glycemic control and to prevent hypoglycemia. The goal of 
SMBG is to collect detailed information about blood glucose levels at many 
  
time points to enable maintenance of a more constant glucose level by more 
precise regimens. It can be used to aid in the adjustment of a therapeutic 
regimen in response to blood glucose values and to help individuals adjust 
their dietary intake, physical activity, and insulin doses to improve glycemic 
control on a day-to-day basis. (23) 
In the study assessed the Impact of Blood Glucose Self-Monitoring on 
Metabolic Control and Quality of Life in Type 2 Diabetic Patients  
The study involved 3,567 patients with type 2 diabetes who were recruited 
by 101 outpatient diabetes clinics and 103 general practitioners 
 findings suggest that SMBG can have an important role in improving 
metabolic control if it is an integral part of a wider educational strategy 
devoted to the promotion of patient autonomy. (24) 
Numerous trials have been carried out to determine the true impact of SMBG 
on glycemic control. Some, including randomized, controlled trials, have 
demonstrated the efficacy of SMBG. Among patients with type 1 diabetes, 
SMBG has been associated with improved health outcomes. Specifically, 
increasing frequency of SMBG was linearly correlated with reductions in 
HbA1c among type 1 patients in Scotland. (26) 
 Among patients with type 2 diabetes, a higher frequency of SMBG was 
associated with better glycemic control among insulin-treated patients who 
were able to adjust their regimen. (27) 
Other studies, however, have suggested that SMBG has not achieved its true 
potential impact as an aid to improving glycemic control.  
Nevertheless, most diabetologists agree that self-management of diabetes 
needs to incorporate some SMBG data, and that motivated patients can 
benefit from the increased empowerment that SMBG yields. Diabetes 
specialists now recommend that patients use SMBG data for day-to-day 
  
regimen changes and that health care professionals use SMBG data to guide 
alterations in medication regimens. The American Diabetes Association has 
sanctioned efforts to teach people with diabetes to use SMBG data actively 
as part of a patient-centered self-management program.  
The process of teaching individuals to manage their diabetes has been 
considered an important part of clinical management since the 1930s. The 
goals of diabetes education are to optimize metabolic control, prevent acute 
and chronic complications, and optimize quality of life while keeping costs 
acceptable. One of the goals of Healthy People 2010 is to increase to 60% 
(from the 1998 baseline of 40%) the proportion of individuals with diabetes 
who receive formal diabetes education. There are significant knowledge and 
skill deficits in 50–80% of individuals with diabetes, and ideal glycemic 
control (HbA1c < 7.0%) is achieved in less than half of persons with type 2 
diabetes. programs and future quantitative analyses, and to identify further 
research needs. 
Stringent glycemic control reduces complications and health care costs for 
people with diabetes. In study assessed the effectiveness of a diabetes self-
management training (DSMT) program at a community clinic. Education 
and a glucometer were provided to 70 people with type 2 diabetes in a 4-
hour class, followed by individual dietitian consults and monthly support 
meetings. Most participants were Hispanic or African American with mean 
age of 49+/-10 years and mean body mass index of 34+/-9. Body weight, 
glycosylated hemoglobin (A1C), medications, and follow-up attendance 
were monitored. After 2 to 12 months of program participation, mean A1C 
improved from 9.7+/-2.4% to 8.2+/-2.0% (P<.001); 61% experienced 
positive medication outcomes. The cost of community clinic DSMT was 
approximately $280 per person per year, $185 for each point reduction in 
  
A1C. This study indicated that community clinic DSMT can improve 
glycemic control at modest cost. (28) 
The study involved 3,567 patients with type 2 diabetes who were recruited 
by 101 outpatient diabetes clinics and 103 general practitioners. Patients 
completed a questionnaire investigating SMBG practice and QoL (diabetes-
related stress, diabetes health distress, diabetes-related worries, and Centers 
for Epidemiologic Studies-Depression scale). Results Data on SMBG were 
available for 2,855 subjects (80% of the entire study population). Overall, 
471 patients (17%) stated that they tested their blood glucose levels at home 
1 time per day, 899 patients (31%) tested their blood glucose levels 1 time 
per week, and 414 patients (14%) tested their blood glucose levels <1 time 
per week, whereas 1,071 patients (38%) stated that they never practiced 
SMBG. A higher frequency of SMBG was associated with better metabolic 
control among subjects who were able to adjust insulin doses, whereas no 
relationship was found in all other patients, irrespective of the kind of 
treatment. Multivariate analyses showed that an SMBG frequency 1 time 
per day was significantly related to higher levels of distress, worries, and 
depressive symptoms in non–insulin-treated patients.  
 findings suggest that SMBG can have an important role in improving 
metabolic control if it is an integral part of a wider educational strategy 
devoted to the promotion of patient autonomy. In patients not treated with 
insulin, self-monitoring is associated with higher HbA1c levels and 
psychological burden. (29)  
For a number of diabetes patients regular care may be insufficient. A 
Multidisciplinary Intensive Education Program (MIEP), based on the 
empowerment approach, has been developed to help patients obtain their 
treatment goals (adequate self-management, glycemic control and quality of 
  
life). The aim of this pilot study is to determine the effects of MIEP and it's 
mechanisms of influence. MIEP consisted of 12 days group-sessions and 
individual counseling. At baseline and 3-months follow-up, blood-glucose 
(HbA1c), quality of life, health locus of control, distress, and knowledge 
were obtained (N = 51). Paired T-tests and regression analyses were 
conducted. HbA1c, and knowledge improved significantly, patients rated 
themselves healthier and were more internal and less powerful others 
oriented. Baseline scores explained effects in HbA1c, and quality of life. 
Locus of control significantly contributed in effects on quality of life. MIEP 
benefited patients with prolonged self-management difficulties, and this 
form of care seems to complement regular care. (30) 
Body weight 
 Obesity prevalence is increasing all over the world. Obese patients are at 
increased risk for developing many medical problems, including insulin 
resistance and type 2 diabetes mellitus, hypertension, dyslipidemia, 
cardiovascular diseases and stroke. Excess body weight is associated with 
substantial increase in mortality from all causes, cardiovascular diseases in 
particular. Weight control is part of the major health priorities identified for 
the future.  
In study  to evaluated the effects of a one-year weight reduction program on 
obesity and its comorbid conditions and to make a model for long term 
weight reducing program.Two hundred obese (ITM > 30 kg/m2) subjects, 
who attended a 15-day weight reduction ("Cigota") program, three times 
during a year, were followed up. Participants from group A strictly adhered 
to the prescribed regimen, while participants from group B followed their 
own routine of diet and physical activity. Two groups were comparable in 
terms of gender, age, duration of obesity, previous and concomitant diseases.  
  
A year later, a statistically significant mean weight loss was established in 
both groups, but it was greater in group A (p<0.05). In both groups, all 
serum lipid parameters, parameters of glycemic control, as well as values of 
systolic and diastolic blood pressures improved. There was a further 
decrease in serum levels of total cholesterol, LDL-cholesterol, and 
LDL/HDL ratio in group A. As compared to group B, group A experienced 
better glycemic control in diabetic and non-diabetic obese patients, and 
enhanced reversion from diabetes to impaired glucose tolerance or normal 
glucose tolerance. This study has demonstrated a well-known fact that body 
mass reduction is associated with a decrease in blood pressure.and 
concluded that, Treatment of obesity can make a substantial contribution to 
reducing hyperlipidemia, improving glycemic control, and treating 
hypertension. Prevention and treatment of obesity may reduce overall 
morbidity and mortality in the years to come.  Suggest starting with weight 
reducing program "Cigota" and combining it with balanced program of diet 
and physical activity until normalizing body weight. (31) 
In patients with type 2 diabetes, obesity is associated with poor glycaemic 
control. In some studies a negative correlation between HbAlc and BMI was 
found in Chinese population. Recent studies comparing south Asian and 
European type 2 diabetic patients also found a lower BMI in the former 
group. In Korean type 2 diabetic patients, non-obese patients had a lower 
fasting serum C-peptide, more pronounced weight loss from time of 
maximal weight and higher percentage of insulin treatment than the obese 
patients. In Korean patients, there were also close associations between 
fasting plasma C-peptide and BMI. In a Swedish study, lean type 2 diabetic 
patients had impaired insulin secretion rather than insulin resistance. In 
Indian type 2 diabetic patients, lean patients had higher HbAlc and fasting 
  
plasma glucose than obese patients. In the UKPDS, patients who failed 
dietary treatment also had low BMI. Taken these findings together, a low 
BMI which reflects underlying insulin deficiency, is of particular relevance  
suggest that insulin deficiency is an important factor contributing to poor 
glycaemic control, especially in the event of non-insulin therapy.  
Obesity is often associated with type 2 (non insulin-dependent) diabetes. A 
growing body of evidence support the hypothesis that these two diseases 
share a common pathogenesis. Nevertheless, experience derived from 
clinical observation on type 2 diabetic patients indicates that reduction of 
body weight is not always accompanied by an improvement in metabolic 
control and that a good metabolic control is often obtained without 
influencing body composition. In study to evaluate the relationship between 
body mass and glycemic control in a type 2 diabetic population by a 3 years 
observational study. A cohort of 562 subjects was studied. At entry more 
than 80% of patients were overweight or obese according to the body mass 
index (BMI) scale and this proportion was not significantly reduced at the 
end of the follow-up. At entry all patients had a glycosylated hemoglobin 
(HbA1c) value above 8.1% whereas at the end of follow-up more than 2/3 of 
patients were in good metabolic control. No relationship was observed 
between modification of body mass and metabolic control. These data 
confirm the high frequency of obesity among type 2 diabetic individuals but 
they suggest that impaired glucose metabolism and alteration of body weight 
have different pathogenesis. (32)  
The relationship between alcohol consumption and insulin resistance shows 
a U-shaped curve: insulin resistance is minimal in individuals with regular 
mild to moderate alcohol consumption and increases in both heavy drinkers 
and subjects without any alcohol consumption. These favourable metabolic 
  
effects on insulin sensitivity of moderate alcohol consumption may explain 
the significant reduction in the development of type 2 diabetes and the risk 
of cardiovascular complications reported in numerous epidemiological 
studies. This latter effect has also reported in patients with diabetes mellitus, 
although this observation remains controversial. However, alcohol 
consumption could increase the global risk of hypoglycaemia, both in the 
fasting state and after a meal (reactive hypoglycaemia) in both diabetic and 
nondiabetic subjects. These latter effects may result from a direct inhibition 
of gluconeogenesis, from a reduced secretion of counterregulatory hormones 
and/or from an alcohol-induced inappropriate behavior. (49) 
A systematic review to see the effect of alcohol consumption on diabetes 
mellitus. Both diabetes mellitus and alcohol consumption are prevalent in 
the United States, yet physicians are poorly informed about how alcohol use 
affects risk for or management of diabetes. A systematic review was 
conducted to assess the effect of alcohol use on the incidence, management, 
and complications of diabetes mellitus in adults. Data from  English-
language studies in persons 19 years of age or older that were identified by 
searching the MEDLINE database from 1966 to the third week of August 
2003 and the reference lists of key articles.Two independent assessors 
reviewed 974 retrieved citations to identify all experimental, cohort, or case-
control studies that assessed the effect of alcohol use on diabetes risk, 
control, self-management, adverse drug events, or complications. Two 
independent reviewers extracted data and evaluated study quality on the 
basis of established criteria. Thirty-two studies that met inclusion criteria 
were reviewed. Compared with no alcohol use, moderate consumption (one 
to 3 drinks/d) is associated with a 33% to 56% lower incidence of diabetes 
and a 34% to 55% lower incidence of diabetes-related coronary heart 
  
disease. Compared with moderate consumption, heavy consumption (>3 
drinks/d) may be associated with up to a 43% increased incidence of 
diabetes. Moderate alcohol consumption does not acutely impair glycemic 
control in persons with diabetes. Conclusions , Moderate alcohol 
consumption is associated with a decreased incidence of diabetes mellitus 
and a decreased incidence of heart disease in persons with diabetes. Further 
studies are needed to assess the long-term effects of alcohol consumption on 
glycemic control and noncardiac complications in persons with diabetes. 
(50) 
There is a growing body of evidence to suggest that smoking is an 
independent risk factor for diabetes and that among people with diabetes, 
smoking aggravates the risk of serious disease and premature death. (33) 
In the US Nurses’ Health Study, 114,247 women were followed for 8 years 
and 2,333 cases of type 2 diabetes were confirmed.  After controlling for 
multiple risk factors,  the relative risk of diabetes was 1.42 among women 
who smoked 25 or more cigarettes a day compared with non-smokers, 
suggesting a moderate association between smoking and the subsequent 
development of diabetes. (33)    
A similar study of 41,810 middle aged men found that those who smoked 
more than 25 cigarettes daily had a relative risk of diabetes of 1.94 
compared with non-smokers. (34)        
A prospective study of Japanese men concluded that age of smoking 
initiation and number of cigarettes smoked were major risk factors for 
developing diabetes. (35)     
Similarly, data from the US Cancer Prevention Study 1 found that as 
smoking increased so the rate of diabetes increased for both men and 
women. (36)      
  
People with diabetes already have an increased risk of heart disease, which 
is further elevated if they smoke.  Diabetes acts in several ways to damage 
the heart: high glucose levels affect the walls of the arteries making them 
more likely to develop fatty deposits which in turn makes it more difficult 
for the blood to circulate. People with diabetes are more likely to have high 
blood pressure and high levels of fats such as triglycerides.  They are also 
more likely to have lower levels of the protective HDL cholesterol. (37) 
Smoking has also been identified as a risk factor for insulin resistance which 
can lead to diabetes.  People with insulin resistance cannot properly use 
insulin and such people may initially have higher than normal amounts of 
insulin circulating in their blood, a condition known as hyperinsulinemia.   
Several factors, including genetics and obesity, increase a person’s risk of 
insulin resistance and smoking has also been shown to increase the risk of 
this condition.  It is believed that catecholamines, a type of hormone, are 
produced in greater quantity in smokers and act as an antagonist to insulin 
action. 3   A study of 40 patients with Type 2 diabetes found insulin 
resistance was markedly aggravated among those who smoked. (38)      
 A recent British prospective study of 7,735 men aged 40-59 years found 
that cigarette smoking was associated with a significant increase in risk of 
diabetes, even after adjustment for age, body mass index, and other potential 
confounding factors.  The benefit of giving up smoking was only apparent 
after  5 years of smoking cessation and risk reverted to that of never-smokers 
only after 20 years.  Men who gave up smoking during the first 5 years of 
follow-up showed significant weight gain and subsequently higher risk of 
diabetes than continuing smokers.  However, the authors concluded that in 
the long term, the benefits of giving up smoking outweigh the adverse 
effects of early weight gain. (39)  
  
 EXERCISE AND TYPE2 DIABETES 
The possible benefits of physical activity for the patient with type 2 diabetes 
are substantial, and recent studies strengthen the importance of long-term 
physical activity programs for the treatment and prevention of this common 
metabolic abnormality and its complications. Specific metabolic effects can 
be highlighted as follows.  
Several long-term studies have demonstrated a consistent beneficial effect of 
regular physical activity training on carbohydrate metabolism and insulin 
sensitivity, which can be maintained for at least 5 years. These studies used 
physical activity regimens at an intensity of 50–80% Vo2max three to four 
times a week for 30–60 min a session. Improvements in HbA1c were 
generally 10–20% of baseline and were most marked in patients with mild 
type 2 diabetes and in those who are likely to be the most insulin resistant. It 
remains true, unfortunately, that most of these studies suffer from inadequate 
randomization and controls, and are confounded by associated lifestyle 
changes. Data on the effects of resistance exercise are not available for type 
2 diabetes although early results in normal individuals and patients with type 
1 disease suggest a beneficial effect. (40) 
It now appears that long-term programs of regular physical activity are 
indeed feasible for patients with impaired glucose tolerance or 
uncomplicated type 2 diabetes with acceptable adherence rates. Those 
studies with the best adherence have used an initial period of supervision, 
followed by relatively informal home physical activity programs with 
regular, frequent follow-up assessments. A number of such programs have 
demonstrated sustained relative improvements in Vo2max over many years 
with little in the way of significant complications. (40) 
 
  
 
 
OBJECTIVES 
 
1. Assessment of glycaemic control in patients with type 2 diabetes 
mellitus followed-up in Gabber Abu Elaaz diabetic center. 
 
2. To identify the impact of patient’s therapeutic education and body 
weight on the glycemic control. 
 
3. To evaluate the efficacy of the patient’s therapeutic education 
program in the center. 
 
 
 
 
 
 
PATIENTS & METHODS 
  
 
This is a cross-sectional study, which was conducted in the Gabber Abu 
Elaaz diabetes clinic at Khartoum area, where all facilities for investigations, 
regular follow-up, dietician, diabetic nurse education program, regarding 
diabetic control, diet, complication awareness, foot care, were available, 
with a catchment population referred to the diabetic clinic, since the start of 
the clinic in 1999, (12952) Patient-average per year = 2590 ), of different 
social class representation. The studied group was selected randomly from 
the referred type 2 diabetic patients, defined according to the 1985 WHO 
criteria. Classification of diabetes was base on clinical presentation, presence 
of ketonuria, and history of diabetic ketoacidosis.  Patients included in this 
study either were referred from clinics in the community or other hospital’s 
clinics or were discharged from hospital’s wards. 
One hundred adult type 2 Diabetic patients 30 year and above, who were on 
regular treatment and follow-up and received therapeutic education were 
randomly selected, including 50 males & 50 females. Every selected diabetic 
patient was interviewed and examined using a questionnaire (attached). 
History from every patient was taken, included the personal data about the 
age, sex, residence occupation, level of formal education, duration of 
diabetes, family history, symptoms of diabetes and its complications. 
Documentation also  included , body weight and height, calculation of body 
mass index , past medical history, smoking and alcohol intake, level of 
education, previous education by dietitians and diabetic nurse, and methods 
of self-monitoring. Body mass index was  calculated as the weight (kg) 
divided by the square of the height (m). Blood pressure was measured, with a 
mercury sphygmomanometer. The higher reading in either arm was taken as 
the final reading. 
  
Complete thorough medical examination was done for every patient . 
All patients were directly interviewed and answered a sum of 24 questions 
regarding their knowledge about diabetes, it’s control, diet, exercise, 
complications and their management, drugs and their complications. 
Correct answers between 18 – 24 questions was considered as good level of 
knowledge, between 12 – 17,was considered as moderate level of 
knowledge, lastly, poor level of knowledge for answering less than 12 
questions.      
Patients were instructed to fast for at least 8 hours, on their clinic visit. 
Venous blood was  taken for measurement of fasting plasma glucose (FPG), 
2Hrs postprandial plasma glucose, glycosylated haemoglobin (HbAlc), 
plasma urea &electrolytes, creatinine, lipid profile including triglyceride 
(TG), total cholesterol (TC).  
The following  normal ranges were taken. 
HBA1c                            < 6.5% 
FBS                                <  120 mg/dl 
S.Urea                            14 – 40 mg/dl 
S. Creatinine                    0.8 – 1.1 mg/dl 
S. Cholesterol                   150 – 200 mg/dl 
S. Triglycerides                 60- 150 mg/dl. 
Statistical analysis was done using the Statistical Package for Social 
Sciences(SPSS)software. 
 
 
  
RESULTS 
The mean age was  (57.9) years, (range 35–85 years), 50 (50%) were men 
and 50 (50%) were women.  
Duration of diabetes (table 1) ,37 patients (37%) have duration of (0-4) 
years,25 patients,(25%) have duration between ,5-9 years,15 
patients,(15%),between,10-14,13 patients between,15-19,7 patients,(7%) 
between,20-24,3patients(3%) between,25-29. 
Level of education (table 2)&(figure 2),46 patient were   illiterate 46%,13 
were males (13%),and 33 were females,(33%),31 patients received primary 
education(31%),21 were males,(21%),10 were females,(10%),16 patients 
received high secondary education(16%),11 were males,(11%),5 were 
females,(5%),and only7 patients,   received university education(7%),5 were 
males,(5%),2 were females,(2%). 
Positive family history of DM,  was found in 68 patients (68%).    
Of the 100 patients with DM, (males & females), only 5 males were smoker, 
(5%), and just one patient admitted to drink alcohol, (1%). 
Treatments modalities (table 4)& (figure 4),14 patients, received just dietary 
advice,(14%),12 were males(12%),and 2 were females (2%),24 patients 
were on insulin treatment (24%),10 were males (10%),14 were females 
(14%),62 of the patients were received ant-diabetic drugs,(62%),28 were 
males,(28%),and,34 were females,(34%),no patient  received combination 
therapy in form of insulin plus anti-diabetic oral drugs. 
Self-monitoring of blood glucose was practised by 11 patients only (11%), 4 
were males (4%), 7 were females, (7%). 
Symptomatology (table 5)&(figure 5) polyuria was found in 46 of the 
patients (46%)22 were males, (22%) ,24 were females (24%),polydipsia in 
28%,anorexia in8%,hyperphagia in 34%,impairement of vision in 53%,chest 
  
painin17%,abdominal pain, in 2%,diarrhea in 6%,constipation in 
17%,vomiting in 2%,syncope in 2%,dizziness in 16%,fatigue in 
56%,weakness in 6%,numbness in 57%,incontinence in 3%,burning 
micturation,26% of males were have impotence, itching in 27% . 
Blood pressure was normal in 74% of the patients. 
Normal fasting blood sugar level, (table 6)&(figure 6) was found  in, 24 
patients(24%)  ,13 patients were males(13%),11 were 
females(11%),48patients(48%)were have FBS ranging between120-
200mg/dl,25were males(25%),23were females(23%),FBS ranging from 201-
300,were found in 22%of the patients(22),10%were males(10),12% females 
(12),fasting blood sugar of 301-400 was found in 4%,1 male(1%),3 
females(3%),FBS, of more than 400mg/dl was found,2% one male and one 
female.     
The mean level of HbAlc was 8.6±1.5% average HbA1c for males was 
(8.75%), and (8.45%) for females, there was slight gender difference in the 
average. The distribution of glycosylated haemoglobin is shown in (Table7) 
( Figure 7). Only  14% good control ( HBA1C <6.5%) 47% of patients(47) 
had HbAlc  (7.6-8.5%) , and a significant proportion of patients (28%) had 
very poor glycaemic control with HbAlc>8.5%.  
Serum cholesterol level (Table 8)&(figure 8), 22 patients(22%) had level 
below 150mg/dl,15 were males(15%),7were females(7%),50 patients had 
serum level,between,150-200,(50%),27%were males,23% were females, i.e. 
within normal range, 28 females had range above 200mg/dl (28%) . 
Triglycerides level,(Table 9)&(figure 9), 6 patients(6%) had level below 
60mg/dl,4 were males(4%),2 were females(2%),60 patients had serum 
level,between,60-150,(60%),27%were males,33% were females, i.e.  66% 
  
within normal range, only 15 females had range above 150mg/dl (15%), 19 
males had range above the normal value (19%). 
Serum urea level,(Table10)&(figure10) , 91 patients were within the normal 
range,(91%),only 9 patients above the normal range,(9%),3 patients were 
males (3%),6 patients were females (6%). 
Serum Creatinine level,(Table 11)&(figure 11), 86 patients were within the 
normal range,(86%),only 14 patients above the normal range,(14%),7 
patients were males (7%),7 patients were females (7%). 
Assessment of degree of knowledge(Table 3)&(figure 3) regarding Diabetes 
Mellitus, diet, management, complications, foot care, follow-up among the 
study group in Gabber Abu Eleez diabetic clinic, all patients were 
interviewed and were asked 24 questions  (questionnaire attached) 
Question one regarding pathopysiology of DM, was answered correctly by 
28 patients (28%) 
Question two, was answered correctly by 79 patients (79%) 
Question three, was answered correctly by 75 patients (75%) 
Question four, was answered correctly by 41 patients (41%) 
Question five, was answered correctly by 32 patients (32%) 
Question six, was answered correctly by 43 patients (43%) 
Question seven, was answered correctly by 93 patients (93%) 
Question eight, was answered correctly by 71 patients (71%) 
Question nine, was answered correctly by 90 patients (90%) 
Question ten, was answered correctly by 83 patients (83%) 
Question 11, was answered correctly by 45 patients (45%) 
Question 12, was answered correctly by 75 patients (75%) 
Question 13, was answered correctly by 83 patients (83%) 
Question 14, was answered correctly by 64 patients (64%) 
  
Question 15, was answered correctly by 82 patients (82%) 
Question 16, was answered correctly by 88 patients (88%) 
Question 17, was answered correctly by 81 patients (81%) 
Question 18, was answered correctly by 70 patients (70%) 
Question 19, was answered correctly by 20 patients (20%) 
Question 20, was answered correctly by 33 patients (33%) 
Question 21, was answered correctly by 28 patients (28%) 
Question 22, was answered correctly by 25 patients (25%) 
Question 23, was answered correctly by 69 patients (69%) 
Question 24, was answered correctly by 82 patients (82%) 
Total number of correctly answered questions were taken as measure of 
degree of knowledge ,18-24,answered correctly were considered as good 
knowledge about DM,12-17,correctly answers were taken as moderate level 
of knowledge, total correctly  answered questions of less than 12were 
considered poor level of knowledge. 
Table (3) & Figure (3,3.1,3.2)  showed that only 32 patients (32%)  were 
having good level of knowledge about Diabetes,22 males (22%),10 were 
females(10%),49 patients. were of moderate degree of knowledge (49%),19 
males (19%),30 females (30%),poor level of knowledge was found in 19% 
of  patients,9%were males,10%,were females. 
BMI, distribution among the patients, the following ranges were taken ,< 
18.5 for underweight,18.5-24.9 as normal,25-29.9 as overweight, 30.0  and 
above as obese (Table 12)&(figure 12,12.1,12.2),showed that ,10% of the 
patients were underweight ,29% were have normal weight , 41%,were 
overweight,20% were obese, no significant gender differences.  
Table (13)& Figure (13) show the correlation between patient’s HBA1c and 
Duration of diabetes, using spearman’s correlation co-efficient, there was no 
  
significant correlation  between the duration of diabetes and 
patient’s(HBA1c) glycemic control. 
Table (14) & Figure (14) show the correlation between patient’s FBS and 
HBA1c, using spearman’s correlation co-efficient; there was significant 
correlation  between the FBS levels and HBA1c levels. 
Table (15) & Figure (15) show the correlation between patient’s HBA1c and 
patient’s BMI, using spearman’s correlation co-efficient, there was no 
significant correlation  between the BMI and patient’s HBA1c (glycaemic 
control). 
Table (16.A) & Figure (16.A) show the correlation between patients FBS 
and Duration of diabetes, using spearman’s correlation co-efficient, there 
was significant correlation  between the duration of diabetes and patient’s 
(FBS). 
Table (16) & Figure (16) show the correlation between patient’s FBS and 
BMI, using spearman’s correlation co-efficient; there was no significant 
correlation  between the BMI and patient’s FBS (glycaemic control). 
Table (17) & Figure (17) show the correlation between patients HBA1c and 
level of knowledge, using spearman’s correlation co-efficient, there was no 
significant correlation  between the level of knowledge and patient’s HBA1c 
(glycemic control). 
Table (18) & Figure (18) shows the correlation between patients FBS and 
level of knowledge, using spearman’s correlation co-efficient, there was no 
significant correlation  between the level of knowledge and patient’s FBS 
(glycaemic control). 
 
 
  
Table (19) & Figure (19) show the correlation between occurrence of 
retinopathy among the diabetic patients and duration of the diabetes, using 
spearman’s correlation co-efficient, there was significant correlation  
between the retinopathy and duration of the disease. 
Table (20)& Figure (20) show the correlation between occurrence of 
neuropathy among the diabetic patients and duration of the diabetes, using 
spearman’s correlation co-efficient, there was  significant correlation  
between the neuropathy and duration of the disease. 
Table (21)& Figure (21) show the correlation between patients serum 
Cholesterol and Serum Triglycerides, using spearman’s correlation co-
efficient, there was no significant correlation  between the two tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
TABLE (1)  
DURATION OF DIABETES AMONG THE PATIENTS 
 
Duration of DM NO. of Patients % 
0-4 37 37% 
5-9 25 25% 
10-14 15 15% 
15-19 13 13% 
20-24 7 7% 
25-29 3 3% 
  
 
 
 
figure:(1) duration of diabetes among the patients
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TABLE (2) 
LEVEL OF EDUCATION AMONG THE PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TYPE OF EDUCATION MALE FEMALE TOTAL 
NON 13 33 46 
PRIMARY 21 10 31 
SECONDARY 11 5 16 
UNIVERSITY 5 2 7 
TOTAL 50 50 100 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE (2) : LEVEL OF EDUCATION AMONG THE PATIENTS
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TABLE (3) 
LEVEL OF DIABETIC KNOWLEDGE AMONG THE PATIENTS 
 
 
 
LEVEL OF KNOWLEDGE  MALE FEMALE TOTAL 
GOOD KNOWLEDGE (18-24) 22 10 32 
MODERATE KNOWLEDGE (12-
17) 19 30 49 
POOR KNOWLEDGE (< 12) 9 10 19 
TOTAL 50 50 100 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE (3) QUESTIONS ANSWERED CORRECTLY BY THE DIABETIC PATIENTS.FOLLOWED 
IN GABIR ABU ELEEZ DIABETIC CENTER 
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FIGURE (3.1) QUESTIONS ANSWERED CORRECTLYBY THE DIABETIC 
PATIENTS.FOLLOWED IN GABIR ABU ELEEZ DIABETIC CENTER  
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FIGURE (3.2) QUESTIONS ANSWERED CORRECTLYBY THE DIABETIC 
PATIENTS.FOLLOWED IN GABIR ABU ELEEZ DIABETIC CENTER  
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FIGURE(3.3) LEVEL OF DIABETIC KNOWLEDGE AMONG THE PATIENTS
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TABLE: (4) 
TREATMENT MODALITIES AMONG THE STUDIED PATIENTS 
 
 
TREATMENT MALE FEMALE TOTAL 
DIET 12 2 14 
INSULIN 10 14 24 
ANTI-DIABETIC DRUGS 28 34 62 
COMBINATION (INSULIN 
+DRUGS) 0 0 0 
TOTAL 50 50 100 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE (4) TREATMENT MODALITIES AMONG THESTUDY DIABETIC PATIENTS.FOLLOWED 
IN GABIR ABU ELEEZ DIABETIC CENTER 
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FIGURE (4.1) TREATMENT MODALITIES AMONGTHESTUDIED DIABETIC 
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TABLE (5)  
SYMPTOMS AMONG THE PATIENTS 
symptoms MALE FEMALE TOTAL 
Polyuria 22 24 46 
polydipsia 16 12 28 
anorexia  2 6 8 
Hyperphagia 20 14 34 
Impairment of vision 6 11 17 
Chest pain 2 2 4 
Sputum 0 0 0 
Abdominal pain 2 0 2 
Diarrhea 3 3 6 
Constipation 9 8 17 
Vomiting 2 0 2 
Syncope 1 1 2 
Dizziness 5 11 16 
Fatigue 33 23 56 
weakness 4 2 6 
Numbness 32 25 57 
Incontinence 2 1 3 
Burning micturation 13 6 19 
Impotence 26 0 26 
Itching 17 10 27 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE (5) SYMPTOMS AMONGTHE STUDIED PATIENTS
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FIGURE (5.1) SYMPTOMS AMONG THE STUDY PATIENTS
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TABLE: (6) 
DISTRIBUTION OF FBS AMONG THE PATIENTS 
 
 
FASTING BLOOD SUGAR MALE FEMALE TOTAL 
< 120 13 11 24 
120- 200 25 23 48 
201- 300 10 12 22 
301-400 1 3 4 
> 400 1 1 2 
TOTAL 50 50 100 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE:(6) FBS LEVELS AMONG THE PATIENTS
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TABLE: (7) 
DISTRIBUTION OF HBA1C LEVELS AMONG THE PATIENTS 
 
 
 
Ranges OF HBA1C Male Female % 
< 6.5 8 6 14% 
6.5-7.5 11 11 22% 
7.6-8.5 11 14 25% 
8.6-9.5 4 4 8% 
9.6-10.5 4 7 11% 
>10.5 12 7 19% 
Total 50 50 100% 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE: (7) LEVELS OF HBA1C 
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TABLE (8)   
DISTRIBUTION OF SERUM CHOLESTEROL LEVELS AMONG THE 
PATIENTS 
 
 
 
RANGE OF S.CHOLESTEROL MALE FEMALE TOTAL 
<      150 15 7 22 
150     -   200 27 23 50 
>     200 8 20 28 
 50 50 100 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE: (8) DISTRIBUTION OF SERUM CHOLESTEROL LEVELS AMONG THE PATIENTS
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TABLE: (9) 
 
DISTRIBUTION OF SERUM TRIGLYCERIDES AMONG THE STUDY PATIENTS 
 
 
RANGES OF TRIGLYCERIDES MALE FEMALE TOTAL 
< 60 4 2 6 
60  -  150 27 33 60 
>  150 19 15 34 
TOTAL 50 50 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE (9) :DISTRIBUTION OF SERUM TRIGLYCERIDES AMONG TYPE 2 DM PAIENTS
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FIGURE (9.1) :DISTRIBUTION OF SERUM TRIGLYCERIDES AMONG TYPE 2
DM MALES
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FIGURE (9.2) :DISTRIBUTION OF SERUM TRIGLYCERIDES AMONG TYPE 2 DM  PAIENTS
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TABLE (10) 
 
LEVEL OF SERUM UREA AMONG THE PATIENTS 
 
 
 
 
S.UREA LEVEL MALE FEMALE TOTAL 
< 14 1 0 1 
14-40 46 46 92 
> 40 3 4 7 
TOTAL 50 50 100 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE(10) LEVELS OF SERUM UREA AMONG PATIENTS
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FIGURE(10.1) LEVELS OF SERUM UREA AMONG PATIENTS
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TABLE (11) 
 
LEVEL OF SERUM CREATININE AMONG THE PATIENTS 
 
 
 
CREATININE LEVEL MALE FEMALE TOTAL 
< 0.8 23 18 41 
0.8-1.0 20 25 45 
> 1.0 7 7 14 
TOTAL 50 50 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
TABLE (12) 
RANGES OF BMI AMONG PATIENTS 
 
 
BMI MALE FEMALE TOTAL 
UNDERWEIGHT ( <18.5 ) 8 2 10 
NORMAL (18.5-24.9) 14 15 29 
OVER WEIGHT (25.0-29.9) 21 20 41 
OBESE (≥30.0 7 13 20 
TOTAL 50 50 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE (12) BMI DISTRIBUTION AMONG PATIENTS 
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FIGURE (12) BMI DISTRIBUTION AMONG PATIENTS 
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Correlations
1.000 .003
. .975
100 100
.003 1.000
.975 .
100 100
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
HBA1C LEVELS
LEVELS OF DURATION
Spearman's rho
HBA1C
LEVELS
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DURATION
TABLE: (13) HBA1C LEVELS *  DURATION OF DIABETES Crosstabulation
Count
3 4 3 2 2 0 14
10 5 1 4 2 0 22
9 7 5 3 0 2 26
4 2 2 0 0 0 8
6 2 1 0 2 0 11
5 4 3 4 2 1 19
37 24 15 13 8 3 100
(<6.5)
(6.5_7.5)
(7.6_8.5)
(8.6_9.5)
(9..6_10.5)
(>10.5)
HBA1C
LEVELS
Total
(0_4) (5_9) (10_14) (15_19) (20_24) (25_29)
 DURATION OF DIABETES
Total
  
FIGURE: (13) 
CORRELATION BETWEEN HBA1c & DURATION OF DIABETES 
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FIGURE: (13-1) 
CORRELATION BETWEEN HBA1c & DURATION OF DIABETES 
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Correlations
1.000 .215*
. .032
100 100
.215* 1.000
.032 .
100 100
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
HBA1C LEVELS
FBS LEVELS
Spearman's rho
HBA1C
LEVELS FBS LEVELS
Correlation is significant at the 0.05 level (2-tailed).*. 
TABLE: (14) HBA1C LEVELS * FBS LEVELS Crosstabulation
Count
6 5 2 1 0 14
5 13 3 1 0 22
7 11 7 0 1 26
3 2 3 0 0 8
2 7 2 0 0 11
1 10 5 2 1 19
24 48 22 4 2 100
(<6.5)
(6.5_7.5)
(7.6_8.5)
(8.6_9.5)
(9..6_10.5)
(>10.5)
HBA1C
LEVELS
Total
(<120) (120_200) (201_300) (301_400) (>400)
FBS LEVELS
Total
  
FIGURE: (14) 
CORRELATION BETWEEN HBA1c & FBS 
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Correlations
1.000 .032
. .757
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Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
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TABLE: (15) HBA1C LEVELS * BMI RANGES Crosstabulation
Count
2 6 4 2 14
2 5 13 2 22
1 9 10 6 26
0 2 4 1 7
1 1 5 4 11
4 5 9 1 19
10 28 45 16 99
(<6.5)
(6.5_7.5)
(7.6_8.5)
(8.6_9.5)
(9..6_10.5)
(>10.5)
HBA1C
LEVELS
Total
UNDER
WEIGHT NORMAL
OVER
WEIGHT OBESE
BMI RANGES
Total
  
 
 
FIGURE: (15) 
CORRELATION BETWEEN HBA1c & BMI 
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FIGURE: (15.2) 
CORRELATION BETWEEN HBA1c & BMI 
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TABLE: (16) BMI RANGES * FBS LEVELS Crosstabulation
Count
1 3 5 0 1 10
7 13 8 0 0 28
10 23 7 4 1 45
6 8 2 0 0 16
24 47 22 4 2 99
UNDER WEIGHT
NORMAL
OVER WEIGHT
OBESE
BMI
RANGES
Total
(<120) (120_200) (201_300) (301_400) (>400)
FBS LEVELS
Total
Correlations
1.000 -.193
. .056
100 99
-.193 1.000
.056 .
99 99
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
FBS LEVELS
BMI RANGES
Spearman's rho
FBS LEVELS BMI RANGES
  
 
FIGURE: (16) 
CORRELATION BETWEEN FBS &BMI 
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TABLE: (16.A)  DURATION OF DIABETES * FBS LEVELS Crosstabulation
Count
15 16 6 0 0 37
7 11 5 1 0 24
0 10 3 2 0 15
0 8 3 1 1 13
2 2 3 0 1 8
0 1 2 0 0 3
24 48 22 4 2 100
(0_4)
(5_9)
(10_14)
(15_19)
(20_24)
(25_29)
 DURATION
OF DIABETES
Total
(<120) (120_200) (201_300) (301_400) (>400)
FBS LEVELS
Total
 
 
 
 
 
 
Correlations
1.000 .372**
. .000
100 100
.372** 1.000
.000 .
100 100
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
FBS LEVELS
LEVELS OF DURATION
Spearman's rho
FBS LEVELS
LEVELS OF
DURATION
Correlation is significant at the 0.01 level (2-tailed).**. 
  
FIGURE: (16.A) 
CORRELATION BETWEEN FBS &DURATION OF DIABETES 
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TABLE: (17) HBA1C LEVELS * KNOWLEDGE.LEVEL Crosstabulation
Count
2 5 7 14
3 14 5 22
8 12 6 26
2 4 2 8
1 8 2 11
3 6 10 19
19 49 32 100
(<6.5)
(6.5_7.5)
(7.6_8.5)
(8.6_9.5)
(9..6_10.5)
(>10.5)
HBA1C
LEVELS
Total
poor moderate good
KNOWLEDGE.LEVELS
Total
  
FIGURE: (17) 
CORRELATION BETWEEN HBA1c & LEVEL OF KNOWLEDGE 
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TABLE:  (18)  LEVELS OF KNOWLEDGE. * FBS LEVELS Crosstabulation
Count
6 5 7 0 1 19
12 24 9 3 1 49
6 19 6 1 0 32
24 48 22 4 2 100
poor
moderate
good
KNOWLEDGE.LEVEL
Total
(<120) (120_200) (201_300) (301_400) (>400)
FBS LEVELS
Total
  
 
FIGURE: (18) 
CORRELATION BETWEEN FBS & LEVEL OF KNOWLEDGE 
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TABLE :( 19) 
 
 
 
 
 
 
  
 
 
RETINOPATHY * LEVELS OF DURATION Crosstabulation
Count
29 21 10 8 2 3 73
8 3 5 5 6 0 27
37 24 15 13 8 3 100
NON
HAVE
RETINOPATHY
Total
(0_4) (5_9) (10_14) (15_19) (20_24) (25_29)
LEVELS OF DURATION
Total
Correlations
1.000 .209*
. .037
100 100
.209* 1.000
.037 .
100 100
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
RETINOPATHY
LEVELS OF DURATION
Spearman's rho
RETINOP
ATHY
LEVELS OF
DURATION
Correlation is significant at the 0.05 level (2-tailed).*. 
  
 
FIGURE: (19) 
CORRELATION BETWEEN DURATION OF DIABETES & 
RETINOPATHY 
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TABLE: (20) 
 
 
 
 
 
 
Correlations
1.000 .252*
. .011
100 100
.252* 1.000
.011 .
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Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
LEVELS OF DURATION
NEUROPATHY
Spearman's rho
LEVELS OF
DURATION
NEUROP
ATHY
Correlation is significant at the 0.05 level (2-tailed).*. 
 
 
 
 
 
 
 
 
NEUROPATHY * LEVELS OF DURATION Crosstabulation
Count
29 17 10 7 1 3 67
8 7 5 6 7 0 33
37 24 15 13 8 3 100
NON
HAVE
NEUROPATHY
Total
(0_4) (5_9) (10_14) (15_19) (20_24) (25_29)
LEVELS OF DURATION
Total
  
FIGURE: (20) 
CORRELATION BETWEEN DURATION OF DIABETES & 
NEUROPATHY 
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TABLE: (21) CHOLESTEROL LEVELS * RANGES OF TRIGLYCERIDE Crosstabulation
Count
1 13 8 22
4 31 15 50
1 16 11 28
6 60 34 100
(<150)
(150_200)
(>200)
CHOLESTEROL
LEVELS
Total
(<=59.9) (60_150) (>=151)
RANGES OF TRIGLYCERIDE
Total
Correlations
1.000 .035
. .728
100 100
.035 1.000
.728 .
100 100
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
RANGES OF
TRIGLYCERIDE
CHOLESTEROL LEVELS
Spearman's rho
RANGES OF
TRIGLYCERI
DE
CHOLESTER
OL LEVELS
  
 
 
FIGURE: (21) 
CORRELATION BETWEEN S.CHOLESTEROL LEVEL & 
S.TRIGLYCERIDES LEVEL 
 
 
(>=151)(60_150)(<=59.9)
RANGES OF TRIGLYCERIDE
70.0%
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
Pe
rc
en
t
39.29%
57.14%
3.57%
30.0%
62.0%
8.0%
36.36%
59.09%
4.55%
(>200)
(150_200)
(<150)
CHOLESTEROL LEVELS
  
DISCUSSION 
 
The management of Diabetes Mellitus requires not only the prescription of 
the appropriate nutritional and pharmacological regimen by the physician 
but also intensive education and counselling of the patient (41). 
Control of obesity and ideal body weight is important for better glycemic 
control and prevention of complications. 
 In the studied patients with type2 diabetes mellitus, the mean age was (57.9) 
years, (range 35–85 years), mean duration of diabetes, was 8.7years.  Most 
of these patients were either illiterate or just received primary education 
(77%), which had an impact on their well understanding of the advice and 
instructions given by diabetes educators, who aim to modify patients’ 
behavior by providing knowledge, changing attitude or teaching skills. 
The symtomatology of these patients gives clear indication to their 
uncontrolled blood sugar levels, and complications which is due to   
fluctuation of these levels. Polyuria, polydipsia, fatigue, numbness, 
impairment of vision, were the most prevalent symptoms. 
Presence of retinopathy & peripheral neuropathy have significant correlation 
to duration of DM (spearman’s correlation coefficient is significant). 
Fasting blood glucose & HBA1c showed that, 76% of these patients had 
FBS levels above the normal range, and only 14% had HBA1c less 6.5% 
,correlation between the two tests was significant using spearman’s 
correlation coefficient, this result goes well with study conducted by, Bonora 
E , who found that, HbA(1c) is more related to pre-prandial than 
postprandial plasma/blood glucose levels. (43).This is also was proved by, 
  
Rohlfing CL,who  defined the relationship between HbA(1c) and PG as 
assessed in the DCCT. (44)  
 Level of the knowledge of the patients visiting the centre  regularly  was 
adequate,81% were between  good level and moderate level of knowledge 
regarding awareness about  diabetes complications & diet ,but  the weakness 
appeared in the aspect of  management and it’s complications . This 
probably is due to inadequate information, non-availability of educational 
material and improper guidance about management of diabetes and 
complications of its medications. The reasons of the poor knowledge need to 
be further studied in detail in our patients. 
Correlations between levels of knowledge and the glycemic control of those 
patients, regarding the HBA1C, Fasting blood sugars levels as parameters of 
control, using spearman’s correlation coefficient didn’t show significant 
correlation between them.  
This in contrast to the study conducted in the regional diabetes clinic at the 
Prince of Wales Hospital (PWH) of Hong Kong, where, they were able to 
demonstrate a correlation between patient’s therapeutic education and 
SBGM, and glycaemic control. (6).  
This correlation also was proved by (Rimm EB, et al 1995) who found in 
both type 1 and type 2 patients, in-patient education programmes and 
outpatient counselling improve glycaemic control.(34). 
The same result was obtained in three different studies, in Asian diabetic 
patients living in England (23). In a study conducted in Papua New Guinea.  
(47). In a study of the effect of culturally appropriate health education on 
glycaemic control and knowledge of diabetes in British Pakistani women 
with type 2 diabetes mellitus. (22). 
  
The insignificant correlation in the studied patients is due their illiteracy and 
lack of comprehension, or the need for more interactive way of teaching.  
The relation between literacy and improvement of knowledge was proved in 
illiterate women who did not do as well as their literate peers, continuing to 
score less on knowledge parameters, they did not show an improvement in 
glycaemic control.(22). Work is needed to discover methods that utilize 
diabetes education address older patients, illiterate groups and those with 
language difficulties. These groups are likely to benefit from specialized 
programs.  
Control of obesity and ideal body weight is important for better glycemic 
control and prevention of complications, but the characteristics of our 
patients were not according to this norm. 
More than 60% of the patients were overweight or obese. Correlation 
between, fasting blood sugar & HBA1c ranges, and BMI using spearman’s 
correlation co-efficient, showed that, there was no significant correlation 
between BMI and glycemic control, however, this is not the case in other 
studies, where Obesity is strongly and causally linked to type2  diabetes. 
Recent data suggests that the prevention of diabetes is feasible if weight 
control is addressed adequately in individuals at high risk. More 
controversially, weight control also has the potential to make a significant 
impact in those with established type 2 diabetes. In the nurses' health study 
index greater than 35 carried a 93-fold increased risk. (46) 
 However, our study goes well with the study conducted in Diabetology and 
Metabolic Disease Unit, I.N.R.C.A., Via della Montagnola, Italy, where no 
relationship was observed between modification of body mass and metabolic 
control. These data confirm the high frequency of obesity among type 2 
  
diabetic individuals but they suggest that impaired glucose metabolism and 
alteration of body weight have different pathogenesis. (42)  
Self-monitoring of blood glucose is a simple and practical procedure 
acceptable for  patients who can afford it and facilitates the  good glycemic 
control but, unfortunately in the studied patients the practice of using 
glucometers was not good, as only (11%) were practised it, this may be 
either due to financial problem, or lack of knowledge and awareness about 
the importance of this practice. 
Overall Exercise practice among our patients was  poor. Only  few had well 
exercise practices. Females were less active than males (22%). Many studies  
confirmed the beneficial role of physical activity in improving glycemic 
control.(45). 
 Given the importance of physical activity to diabetes management, the 
reduced physical activity in this study is most probably due to aging or 
unawareness about the importance of exercise, raising the concerns among 
patients is necessary that all patients should be encouraged to increase their 
physical activity. 
 
 
 
 
 
 
 
 
 
 
  
 
CONCLUSIONS 
 
• Most patients with type2 diabetes mellitus followed-up in the centre 
were poorly controlled as assessed by their fasting blood sugar and 
Glycated haemoglobin levels. 
• The degree of knowledge is acceptable as more than 80% had either  
good or moderate level of knowledge. 
• There is significant correlation between the fasting blood sugar levels 
and HBA1c levels. 
• There is significant correlation between the fasting blood sugar levels 
and duration of diabetes. 
• There is no significant correlation between fasting blood sugar, 
HBA1c and level of knowledge. 
• There is no significant correlation between fasting blood sugar, 
HBA1c and body mass index. 
• There is significant correlation between retinopathy& neuropathy and 
duration of diabetes. 
• Medical service provided to those patients in the centre is 
satisfactory.  
 
 
 
 
 
 
 
  
 
RECOMMENDATIONS 
 
1. Programs should be planned, which can lead to better concepts of 
healthy food consumption among patients. 
2. To educate the patients about ideal body weight as well as avoidance 
of obesity. 
3. To educate Patients to self-monitor plasma glucose and how use 
glucometers.    
4. Special programs should be planned for older patients, illiterate 
groups and those with language difficulties.  
5. Simple educational tools and well trained educators are needed.  
6. Public education to increase awareness about the disease is needed. 
7. Proper knowledge regarding preventive and management techniques 
and exercise should be improved. 
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